Search results
Results from the WOW.Com Content Network
Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [19] [20] The most common side effects are joint and muscle pain in the arms or legs. [21]
Medicare covers Reclast when it’s deemed medically necessary for the treatment of osteoporosis. The typical dosage is a 5-milligram (mg) infusion that you receive annually as a treatment or once ...
Prolia (denosumab) is an injectable medication that helps treat osteoporosis. Osteoporosis is a condition that causes the bones to become thin and weak, leading to a higher risk of fractures and ...
Examples of bisphosphonates: : Zoledronic acid (Reclast, Zometa), Risedronate (Actonel), Alendronate (Fosamax), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Tiludronate (Skelid). [32] Denosumab. Denosumab is a monoclonal antibody [33] [34] which is administrated subcutaneously. It inhibits osteoclast differentiation and ...
Prolia, approved in 2010 to treat bone loss in postmenopausal women and later approved to treat men and women at high risk of fracture, brought in total third-quarter sales of $986 million.
In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the femur (thigh bone) in the shaft (diaphysis or sub-trochanteric region) of the bone, rather than at the femoral neck, which is the most common site of fracture. However, these fractures are rare (12 in 14,195 women ...
For premium support please call: 800-290-4726 more ways to reach us
Denosumab is an FDA-approved fully human monoclonal antibody to RANKL and during pre-clinical trials was first used to treat postmenopausal patients suffering with osteoporosis (PMO). [ 21 ] [ 22 ] In denosumab's third stage of the FDA's clinical trial, it was shown to: (1) decrease bone turnover, (2) reduce fractures in the PMO population, and ...